Chugai deal positions Circadian as "dominant" player in VEGF-D rights
This article was originally published in Scrip
Roche's Japanese subsidiary, Chugai, has granted the Australian bioventure Circadian exclusive worldwide rights to its intellectual property (IP) estate in the area of vascular endothelial growth factor D (VEGF-D).
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: Bayer’s Phase III failure; US group seeks Japan changes; AstraZeneca winning AKT race for now; NASH developments at AASLD; and the Q3 impact of China’s corruption campaign.
In this week's podcast edition of Five Must-Know Things: AstraZeneca CEO on obesity and more; biotech’s rollercoaster ride set to continue; new Wegovy data; Novo’s plans for semaglutide in NASH; and Zepbound set to become biggest drug ever?
Astellas makes targeted acquisition of small, private US venture in apparent move to shore up its prostate cancer franchise amid a looming major patent expiry.